StockData

Solid Biosciences vs Scholar Rock

SLDB and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SLDB and SRRK compare

Scholar Rock is the larger company, worth 8.2 times as much as Solid Biosciences ($5.5B against $668M).

Solid Biosciences scores higher on the StockData Score (7 against 2 for Scholar Rock), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSLDBSRRK
Size and price
Market cap$668M$5.5B
Share price$6.23$45.08
Change, 1 year46.9%20.5%
Change, 5 years−77.8%67.1%
Beta (5Y)1.460.83
Employees121289
StockData Score
Total score7 (better)2
Valuation score1 (better)0
Growth score00
Performance score00
Health score6 (better)2
Dividend score00
Valuation
P/B1.8× (better)21.6×
FCF yield−23.6%−5.4% (better)
Profitability
Return on equity–−168%
Financial health
Debt / equity0.000.77 (better)
Interest coverage–−38.0×
Current ratio13.82 (better)7.02
Altman Z-score4.706.59 (better)
Piotroski F-score–1
Dividends and buybacks
Buyback yield–−4.6%
Shareholder yield0.00% (better)−4.6%
Ownership
Held by institutions107%114%
Held by insiders26.7%28.9%
Insider net buying, 12 months−$2.7M (better)−$7.4M
Short interest, % of float16.9%27.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.